Gilead Sciences, Inc. has entered into an Agreement and Plan of Merger with CymaBay Therapeutics, Inc., and will commence a tender offer to purchase all outstanding shares of CymaBay at $32.50 per share.
AI Assistant
GILEAD SCIENCES INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.